<DOC>
	<DOCNO>NCT01233570</DOCNO>
	<brief_summary>An assessment efficacy topical tacrolimus treatment cutaneous crohn disease</brief_summary>
	<brief_title>Topical Tacrolimus 0.1 % Ointment For Treatment Of Cutaneous Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>willingness capability follow study procedure confirm diagnosis Crohn 's Disease least 3 month duration confirm radiography , endoscopy pathological examination require skin manifestation Crohn 's disease require give write informed consent male female subject reproductive potential require acceptable form birth control duration study longstanding , concomitant immunosuppressive therapy allow dose stable control skin problem know sensitivity tacrolimus change aminosalicylate dosage four week prior screen oral steroid 40mg per day commence methotrexate , azathoprine ciclosporin within last two month commence TNFalpha monoclonal antibody within three month prior screen patient stoma fashion less three month enrolment patient immunocompromising disease patient diagnosis malignancy within last five year patient condition , past present treatment think investigator render subject ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Cutaneous Crohns Disease</keyword>
	<keyword>Topical Tacrolimus</keyword>
	<keyword>Protopic</keyword>
	<keyword>Metastatic Crohns Disease</keyword>
	<keyword>Pyoderma Gangrenosum</keyword>
	<keyword>Granulomatous chelitis</keyword>
	<keyword>Oral crohn disease</keyword>
	<keyword>Perianal crohn disease</keyword>
</DOC>